Media coverage about RedHill Biopharma (NASDAQ:RDHL) has trended somewhat positive on Sunday, according to Accern. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. RedHill Biopharma earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.0079534900614 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of RedHill Biopharma (NASDAQ RDHL) opened at $5.17 on Friday. The company has a market capitalization of $109.98, a price-to-earnings ratio of -1.91 and a beta of 0.40. RedHill Biopharma has a fifty-two week low of $4.30 and a fifty-two week high of $11.25.
A number of research analysts have recently weighed in on RDHL shares. Zacks Investment Research upgraded RedHill Biopharma from a “sell” rating to a “hold” rating in a report on Wednesday, September 20th. HC Wainwright restated a “buy” rating and issued a $36.00 target price (up previously from $33.00) on shares of RedHill Biopharma in a report on Wednesday, October 4th. Roth Capital restated a “buy” rating and issued a $27.00 target price on shares of RedHill Biopharma in a report on Wednesday, October 4th. Finally, Seaport Global Securities started coverage on RedHill Biopharma in a report on Friday, October 6th. They issued a “buy” rating and a $19.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $21.10.
About RedHill Biopharma
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.